Compare OLP & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | VOGX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 550.9M | 475.4M |
| IPO Year | 1995 | 2026 |
| Metric | OLP | VOGX |
|---|---|---|
| Price | $23.10 | $32.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.75 | N/A |
| AVG Volume (30 Days) | 50.1K | ★ 196.0K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | ★ 7.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $82,740,000.00 | N/A |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $3.71 | N/A |
| P/E Ratio | $23.20 | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $19.62 | $14.80 |
| 52 Week High | $25.88 | $35.50 |
| Indicator | OLP | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 80.60 |
| Support Level | $23.31 | $27.96 |
| Resistance Level | $23.63 | $35.06 |
| Average True Range (ATR) | 0.42 | 3.60 |
| MACD | -0.08 | -0.40 |
| Stochastic Oscillator | 16.42 | 63.10 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred and two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.